A Phase 3 interventional study of RPH-104 in Familial Mediterranean Fever and FMF, sponsored by R-Pharm. Not yet recruiting at 3 sites in Russia. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by R-Pharm · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective is to evaluate the main pharmacokinetic (PK) parameters, efficacy, and safety of goflikicept (GFC) in children and adolescents with colchicine-resistant or colchicine-intolerant familial Mediterranean fever (FMF).
This is an open-label, non-randomized clinical study in pediatric and adolescent participants.
The study consists of three periods:
treatment period, up to 56 weeks including:
The total maximum duration of participation of one participant in the study is up to 76 weeks, i.e. approximately 1 year and 6 months.
The study enrolls participants in two sequential cohorts. Cohort 1 includes 6 adolescents aged 12-14 years in the Kingdom of Saudi Arabia (KSA) and 12-17 years in other countries. An interim safety and pharmacokinetic (PK) analysis will be performed. If enrollment of participants aged 5-17 years is considered feasible, Cohort 2 enrolls participants aged 5-14 years in the KSA and 5-17 years in other countries, until at least 18 participants receive the investigational treatment.
61 studies on the registry are indexed under Familial Mediterranean Fever; 27 are open to participants now.
This study's planned enrollment of 18 is below the median of 40 across 27 interventional studies indexed under Familial Mediterranean Fever.
Browse Familial Mediterranean Fever studies →R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female participants aged ≥ 5 and \< 18 years at the time of signing Form (ICF) and Visit 1, respectively:
2.1. In Kingdom of Saudi Arabia, the upper age limit is 14 years (i.e. the participants should be between ≥ 5 and ≤ 14 years old)
2.2. In other countries, the upper age limit is 18 years (i.e. the participants should be between ≥ 5 and \< 18 years old)
Availability of one of the documented data listed below (at the time of the start of screening) (records of medical examinations/consultations including those done by the investigator, hospital discharges) confirming:
4.1. colchicine resistance at the maximum tolerated therapeutic dose (depending on age and weight) confirmed by the persistence of at least one attack of the disease per month on average, despite the indicated therapy for at least the last 3 months before the start of screening. Colchicine administration will be continued at stable dose if it is not associated with unacceptable adverse drug reactions
4.2. intolerance to therapeutic or subtherapeutic doses of colchicine (presence of unacceptable adverse drug reactions). The dose of colchicine should be stable for at least 5 days before the participant is enrolled (before screening)
One active attack with a duration of no more than 2 days (48 hours) at the time of Visit 1 defined as the development of both clinical and serological signs of an attack including:
Exclusion Criteria:
Conditions or signs which, according to the investigator, suggest impaired (reduced) immune response and/or significantly increase the risk of immunomodulating therapy including (but not limited to):
3.1. any acute or chronic active infection at the time of screening, an infection requiring antimicrobial therapy within 4 weeks prior to screening, or a history of serious, opportunistic, or frequently recurring infection within 6 months prior to screening
3.2. presence of infection caused by the (HIV), virus or virus
History of active or latent tuberculosis (TB) or existing risk factors or signs suggestive of active or latent M. tuberculosis including (not limited to) the following:
4.1. living or working in specific conditions that increase the risk of contact with participants with TB, such as residential care, places of deprivation of liberty, communities of persons without a special place of residence, etc. during the last year before the start of the treatment period
4.2. close contact, i.e. living at the same premises (at home or in another enclosed environment) for a prolonged period of time (several days or weeks, rather than minutes or hours) with a person with active pulmonary TB during the last year before the start of the treatment period
4.3. results of examinations indicating active or latent infection with M. tuberculosis: positive QuantiFERON-TB / T-SPOT.TB test at screening; chest Xray/CT findings confirming pulmonary TB during screening
Previous administration of:
Any of the deviations in the laboratory tests below:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RPH-104 subcutaneously at 2.2 mg/kg on Day 0, followed by 1.1 mg/kg on Days 7 and 14 and then every 2 weeks (q2w). The dose may be increased to 2.2 mg/kg q2w (maximum 160 mg) in non-responders or participants with recurrent familial Mediterranean fever (FMF) attacks.
Biological: RPH-104
solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial.
Also known as: Arcerix, goflikicept
Maximum serum concentration of goflikicept (Cmax (W16))
Time frame: Visit 1 (Baseline) to Visit 10 (Week 16)
Area under serum concentration-time curve for goflikicept (AUC(0-W16))
Time frame: Visit 1 (Baseline) to Visit 10 (Week 16)
Changes in trough serum goflikicept concentration
Time frame: Visit 1 (Baseline) to Visit 10 (Week 16), and Visit 16 (Week 56)
Trough serum steady-state concentration of goflikicept (Cmin,ss)
Time frame: Visit 1 (Baseline) to Visit 10 (Week 16), and Visit 16 (Week 56)
Area under curve for the dosing interval (t) at steady state (ss) after repeated injections (AUC0-t,ss)
Time frame: Visit 1 (Baseline) to Visit 10 (Week 16), and Visit 16 (Week 56)
Time to steady state
Time frame: Visit 1 (Baseline) to Visit 10 (Week 16), and Visit 16 (Week 56)
Percentage of participants with a complete response to treatment
Complete response is defined as resolution of a "marker" familial Mediterranean fever (FMF) attack by day 7 and the absence of recurrent (new) attacks during the treatment period.
Time frame: Up to Visit 16 (Week 56)
Change from baseline in PGA (Physician Global Assessment) score
The Physician's Global Assessment (PGA) is an investigator-rated 5-point scale used to evaluate overall disease activity. Scores range from 0 to 4, where: 0 = none; 1 = minimum; 2 = mild; 3 = moderate; 4 = severe signs and symptoms. Higher scores indicate greater disease severity.
Time frame: at Visit 1 (Baseline) and Visit 16 (Week 56)
Change from baseline in C-reactive protein (CRP) level
Time frame: at Visit 1 (Baseline) and Visit 16 (Week 56)
Change from baseline in serum amyloid A (SAA) level
Time frame: at Visit 1 (Baseline) and Visit 16 (Week 56)
Percentage of participants with serological remission (C-reactive protein < 10 mg/L)
Serological remission is defined as a C-reactive protein (CRP) level of less than 10 mg/L.
Time frame: Up to Visit 16 (Week 56)
Time to a recurrent (new) FMF attack in participants with a resolved "marker" attack
Recurrent (new) Familial Mediterranean Fever (FMF) attack is defined as the presence of both clinical and serological signs of an attack after resolution of the "marker" attack.
Time frame: Visit 2 (Week 1) to Visit 16 (Week 56)
Percentage of participants who were administered an increased dose of goflikicept 2.2 mg/kg once every 2 weeks
Time frame: Up to Visit 16 (Week 56)
Frequency, Severity, Nature, and Outcomes of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Adverse event (AE) severity is assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.
Time frame: Up to Visit 16 (Week 56)
Percentage of participants with anti-drug antibodies (ADA)
Time frame: Up to Visit 16 (Week 56)
Number of participants with clinically significant laboratory abnormalities
Laboratory parameters include: * Hematology * Blood Biochemistry * Measurement of the concentration of immunoglobulin type G (IgG) * Urinalysis
Time frame: Up to Visit 16 (Week 56)
Number of participants with clinically significant vital sign abnormalities
Measurement of vital signs includes: * body temperature (in degrees Celsius) * blood pressure (BP) (one arm, mm Hg) * heart rate (HR) (bpm) * respiratory rate (RR) (per min)
Time frame: Up to Visit 16 (Week 56)
Percentage of participants with Physician Global Assessment (PGA) score < 2 at each visit
The Physician's Global Assessment (PGA) is an investigator-rated 5-point scale used to evaluate overall disease activity. Scores range from 0 to 4, where: 0 = none; 1 = minimum; 2 = mild; 3 = moderate; 4 = severe signs and symptoms. Higher scores indicate greater disease severity.
Time frame: Up to Visit 16 (Week 56)
Сhange from baseline in the overall disease activity assessed by the participant/parent (Visual analogue scale)
Assessment of the disease activity by the subject/legal representative is performed using a visual analog scale (VAS) in mm (0-100), where 0 mm = very good, 100 mm = very bad.
Time frame: at Visit 1 (Baseline) and Visit 16 (Week 56)
Percentage of participants with a partial response
Partial response is defined as resolution of a "marker" familial Mediterranean fever (FMF) attack by day 7 and the presence of recurrent (new) attacks during the treatment period.
Time frame: Up to Visit 16 (Week 56)
Percentage of participants with normal serum amyloid A levels
Percentage of participants whose serum amyloid A (SAA) levels return to normal (\<10 mg/L) at each study visit.
Time frame: Up to Visit 16 (Week 56)
Percentage of participants receiving additional symptomatic therapy
Includes additional symptomatic therapy with nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol (acetaminophen), or glucocorticoids.
Time frame: Up to Visit 16 (Week 56)
Percentage of participants who prematurely discontinued therapy due to Adverse Events (AEs)
Time frame: Up to Visit 16 (Week 56)
Percentage of participants with neutralizing antibodies (NAb)
Time frame: Up to Visit 16 (Week 56)
Number of participants with clinically significant electrocardiogram (ECG) abnormalities
Time frame: Up to Visit 16 (Week 56)
Start is estimated for Dec 2026; primary completion for May 2029, 29 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Goflikicept
Familial Mediterranean Fever →